Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $24,540.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $12.27, for a total transaction of $24,540.00. Following the transaction, the president now directly owns 2,932,467 shares in the company, valued at approximately $35,981,370.09. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock opened at $12.45 on Friday. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $27.45. The business has a 50-day moving average of $12.71 and a 200-day moving average of $12.64.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of GYRE. FMR LLC acquired a new position in shares of Gyre Therapeutics in the 3rd quarter valued at approximately $47,000. Barclays PLC grew its position in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics in the second quarter worth $123,000. Renaissance Technologies LLC acquired a new stake in Gyre Therapeutics in the second quarter valued at $166,000. Finally, Bank of New York Mellon Corp bought a new position in Gyre Therapeutics during the 2nd quarter valued at $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.